Residual macrovascular risk in 2013: what have we learned?

In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.

Source: Cardiovascular Diabetology - January 24, 2014 Category: Cardiology Authors: Jean-Charles FruchartJean DavignonMichel HermansKhalid Al-RubeaanPierre AmarencoGerd AssmannPhilip BarterJohn BetteridgeEric BruckertAda CuevasMichel FarnierEle FerranniniPaola FiorettoJacques GenestHenry GinsbergAntonio GottoDayi HuTakashi KadowakiTatsuh Source Type: research